I-Cybin Therapeutics, inkampani ezimele yokwelapha nge-bioscience esemkhankasweni wokuthola nokuthuthukisa izimiso zokwelapha ezisizwa yi-psilocybin, inelayisensi ye-PEX010 (25 mg) yakwa-Filament ukuze isetshenziswe ovivinyweni. Ukuhlolwa kulindeleke ukuthi kuqale ku-Q3'22 futhi kuzobandakanya abantu abanenkinga enkulu yokucindezeleka abathola ukwelashwa okukhethekile kwe-serotonin reuptake inhibitor (SSRI), okuvame ukusetshenziselwa ukwelapha ukucindezeleka, kanye nalabo abangenalwazi lwe-SSRI.

"Ukugunyazwa kwe-Health Canada kuwubufakazi bokuthi lolu cwaningo luyiqiniso kanye nekhono likaFilament lokukhiqiza kanye nelayisensi abazongenela ukhetho lwemithi yezitshalo," kusho iSikhulu Esiphezulu seFilament, uBenjamin Lightburn. "Umphumela wokwelashwa kwe-psilocybin ezigulini ezithatha imishanguzo yendabuko ye-SSRI iwuphenyo olubaluleke kakhulu futhi sijabule ngokubamba iqhaza kulolu cwaningo olubalulekile."

“Abantu abaningi baseCanada abalwa nokucindezeleka bathola ukwelashwa kwe-SSRI, futhi kuze kube manje, lokhu ngokuvamile kusho ukukhishwa ezivivinyweni zokwelashwa ezisiza ingqondo yengqondo (PAP),” kusho uJosh Taylor, uMsunguli weCybin Therapeutics. “Uma kungase kuboniswe ukuthi i-PAP inganikezwa ngokuphepha nangempumelelo iziguli eziku-SSRIs, abaningi bazozuza. Sibona sengathi leli kuyithuba elihle kakhulu lokukhombisa i-Health Canada ukuthi i-Cybin Therapeutics ingathuthukisa imiphumela yesiguli ngeqembu lethu kanye nezinqubo ezilandelwayo. ”

I-Filament iphinde yanikeza ilayisense i-PEX010 (25 mg) ku-CT ukuze uthole izivivinyo zomtholampilo ezengeziwe zesigaba sesi-2, okulindeleke ukuthi ziqale ngekwata yesine ka-2022. Zombili izinhlolo zizoholwa uDkt. Reg Peters noDave Phillips.